CompletedNot Applicable

Vitamin D3 Supplementation in Patients With HIV: Effects on Interleukin-6 Levels and CD4 Counts

Indonesia20 participantsStarted 2025-06-01

Plain-language summary

This study aims to evaluate the effect of Vitamin D3 supplementation on inflammatory markers and immune status in patients with HIV who are receiving antiretroviral therapy. Participants will receive Vitamin D3 supplementation for 3 months. Outcomes including Interleukin-6 levels and CD4 counts will be measured to assess the potential benefits of this intervention.

Who can participate

Age range19 Years – 59 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with HIV stage 1 or 2 who have been receiving antiretroviral therapy (ART) with a TLD regimen for at least 6 months at Dr. Moewardi General Hospital, Surakarta, Indonesia * Age 19 to 59 years * Willing to participate in the study and provide informed consent * Not currently taking any other vitamin supplements Exclusion Criteria: * Patients who discontinue treatment (dropout) or die during the study period * Patients who experience allergic reactions to Vitamin D3 supplementation

What they're measuring

Change in Interleukin-6 (IL-6) Levels

Timeframe: Baseline to 3 months

Change in CD4 Counts

Timeframe: Baseline to 3 months

Trial details

NCT IDNCT07553052

SponsorUniversitas Sebelas Maret

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-08-31

View on ClinicalTrials.gov More Human Immunodeficiency Virus (HIV) trials